Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 6
1978 3
1979 3
1980 4
1981 2
1982 5
1983 2
1984 1
1985 7
1986 4
1987 9
1988 5
1989 8
1990 4
1991 2
1992 4
1993 4
1994 4
1995 2
1996 3
1997 8
1998 10
1999 8
2000 10
2001 9
2002 11
2003 8
2004 14
2005 17
2006 11
2007 18
2008 18
2009 21
2010 29
2011 21
2012 33
2013 27
2014 23
2015 29
2016 33
2017 25
2018 20
2019 21
2020 18
2021 22
2022 13
2023 7
2024 10
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

514 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout.
Lorenzo JPP, Sollano MHMZ, Salido EO, Li-Yu J, Tankeh-Torres SA, Wulansari Manuaba IAR, Rahman MM, Paul BJ, Mok MY, De Silva M, Padhan P, Lim AL, Marcial M, Vicera JJ, Haq SA, Salman S, Liyanage CK, Keen HI, Yew Kuang C, Wei JC, Hellmi RY, Chan CE Jr, Louthrenoo W. Lorenzo JPP, et al. Among authors: mok my. Int J Rheum Dis. 2022 Jan;25(1):7-20. doi: 10.1111/1756-185X.14266. Epub 2021 Dec 20. Int J Rheum Dis. 2022. PMID: 34931463
Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver.
Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, Zhang L, Liang Z, Liu X, Xiong Z, Zeng X, Wang J, Lu J, Li J, Sun H, Tian X, Yeung PC, Hou Y, Lee HM, Lam CCH, Leung HHW, Chan AWH, To KF, Wong J, Lai PBS, Ng KKC, Wong SKH, Wong VWS, Kong APS, Sung JJY, Cheng ASL. Tang W, et al. Among authors: mok mts. Cell Mol Immunol. 2022 Jul;19(7):834-847. doi: 10.1038/s41423-022-00872-3. Epub 2022 May 20. Cell Mol Immunol. 2022. PMID: 35595819 Free PMC article.
Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis.
Zeng X, Zhou J, Xiong Z, Sun H, Yang W, Mok MTS, Wang J, Li J, Liu M, Tang W, Feng Y, Wang HK, Tsang SW, Chow KL, Yeung PC, Wong J, Lai PB, Chan AW, To KF, Chan SL, Xia Q, Xue J, Chen X, Yu J, Peng S, Sung JJ, Kuang M, Cheng AS. Zeng X, et al. Among authors: mok mts. Cell Mol Immunol. 2021 Apr;18(4):1005-1015. doi: 10.1038/s41423-020-00534-2. Epub 2020 Sep 2. Cell Mol Immunol. 2021. PMID: 32879468 Free PMC article.
The transcription complex p52-ETS1 is essential for germinal center formation.
Morgan D, Zhang B, Fidan K, Pan W, Vaiyapuri TS, Raju A, Hei D, See TY, Sari IN, Chan JW, Majee P, Balachander A, Yu J, Wong AH, Mok MMH, Foo SH, Tang WL, Ang N, Tan I, Peng YF, Jaynes P, Xu S, Ghosh G, Shahabi S, Jeyasekharan AD, Ikawa M, Zhang Y, Howland SW, Lau MC, Wang VY, Lam KP, Tergaonkar V. Morgan D, et al. Among authors: mok mmh. Nat Immunol. 2025 Sep;26(9):1553-1566. doi: 10.1038/s41590-025-02236-1. Epub 2025 Jul 25. Nat Immunol. 2025. PMID: 40715659
ZBTB48 is a priming factor regulating B-cell-specific CIITA expression.
Rane G, Kuan VLS, Wang S, Mok MMH, Khanchandani V, Hansen J, Norvaisaite I, Zulkaflee N, Yong WK, Jahn A, Mukundan VT, Shi Y, Osato M, Li F, Kappei D. Rane G, et al. Among authors: mok mmh. EMBO J. 2024 Dec;43(24):6236-6263. doi: 10.1038/s44318-024-00306-y. Epub 2024 Nov 19. EMBO J. 2024. PMID: 39562739 Free PMC article.
Features of spondyloarthritis around the world.
Lau CS, Burgos-Vargas R, Louthrenoo W, Mok MY, Wordsworth P, Zeng QY. Lau CS, et al. Among authors: mok my. Rheum Dis Clin North Am. 1998 Nov;24(4):753-70. doi: 10.1016/s0889-857x(05)70040-5. Rheum Dis Clin North Am. 1998. PMID: 9891709 Review.
Runx Family Genes in Tissue Stem Cell Dynamics.
Wang CQ, Mok MM, Yokomizo T, Tergaonkar V, Osato M. Wang CQ, et al. Among authors: mok mm. Adv Exp Med Biol. 2017;962:117-138. doi: 10.1007/978-981-10-3233-2_9. Adv Exp Med Biol. 2017. PMID: 28299655 Review.
Clinical Scenarios for Discordant Anti-Xa.
Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, Teng TH, Jan R, Mok M, Vera-Aguilera C, Moreno-Aguilera E. Vera-Aguilera J, et al. Among authors: mok m. Adv Hematol. 2016;2016:4054806. doi: 10.1155/2016/4054806. Epub 2016 May 12. Adv Hematol. 2016. PMID: 27293440 Free PMC article. Review.
514 results